Study on the Safety and Efficacy of Different Doses of Esketamine Combined with Remimazolam Toluene Sulfonate in Painless Bronchoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049351

Enrollment

Unknown

Registered

2021-07-31

Start date

2021-08-10

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchoscopy

Interventions

group A:esketamine (0.1mg/ kg)

placebo group:placebo

group B:esketamine (0.2mg/ kg)

group C:esketamine (0.3mg/ kg)

group C:esketamine (0.4mg/ kg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.All patients underwent painless bronchoscopy in our hospital; 2.Bronchoscopy time no more than 30 minutes; 3.The study was approved by the Hospital Ethics Committee and patients voluntarily participated in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1.History of lobectomy or tracheobronchial stenosis; 2.Unconsciousness, abnormal intelligence and cognition; 3.Allergic reactions to drugs used in research; 4.Long-term use of narcotic or other analgesics; 5.Severe cardiovascular disease, coagulation dysfunction or patient rejection of painless bronchoscopy; 6.History of heart and lung disease, diabetes.

Design outcomes

Primary

Measure	Time frame
mean arterial pressure;heart rate;Ramsay score;oxygen saturation;noradrenaline;cortisol;adrenocorticotropic hormone;blood sugar;	—

Secondary

Measure	Time frame
cough symptoms;patient satisfaction score;anesthesia time, examination time, wake up time;	—

Countries

China

Contacts

Public ContactWu Jiyong

Shandong Provincial ENT Hospital (Shandong Provincial Western Hospital)

wujiyong521@163.com+86 13589117921

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026